Naureen Quibria
Stock Analyst at Capital One
(0)
# 5085
Out of 5,270 analysts
15
Total ratings
9.09%
Success rate
-45.75%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Biomea Fusion | Initiates Coverage On: Overweight | 25 | 2.63 | 850.57% | 1 | Aug 29, 2024 | |
Immutep | Initiates Coverage On: Overweight | 10 | 1.86 | 437.63% | 1 | May 17, 2024 | |
Erasca | Initiates Coverage On: Overweight | 8 | 1.28 | 525% | 1 | Mar 11, 2024 | |
CARISMA Therapeutics | Initiates Coverage On: Overweight | 10 | 0.4 | 2400% | 1 | Oct 3, 2023 | |
Immunocore Hldgs | Initiates Coverage On: Overweight | 84 | 28.89 | 190.76% | 1 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 8.26 | 384.26% | 1 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 11 | 6.78 | 62.24% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | 5.08 | 37.8% | 2 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 21 | 3.7 | 467.57% | 1 | Jan 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | n/a | n/a | 1 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 180 | 0.81 | 22122.22% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Mar 16, 2021 |